[PDF] ENCePP Plenary meeting 12 November



Previous PDF Next PDF







ANNEXI SUMMARY OF PRODUCT CHARACTERISTICS

Erbitux 5mg/mLsolution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each mLof solution for infusion contains 5mg cetuximab Each vial of 20mLcontains 100mg cetuximab Each vial of 100mLcontains 500mg cetuximab Cetuximab is a chimeric monoclonal IgG1antibody produced in a mammalian cell line (Sp2/0) by recombinant DNA technology



ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI

Cetuximab nu prezintă utilizare relevantă la copii și adolescenți în indicațiile aprobate Mod de administrare Erbitux 5mg/ml se administrează intravenos, cu ajutorul unei pompe de perfuzie, al unui picurător gravitațional sau al unui injectomat (pentru instrucțiuni privind manipularea, vezi pct 6 6 )



Erbitux (cetuximab) - Merck Group

Erbitux® (cetuximab) May 2017 Merck Oncology PROGNOSIS The active substance in Erbitux, cetuximab, is a monoclonal antibody A monoclonal antibody is a type of protein that has been designed to recognize and attach to a specific structure (called an antigen) in the body Erbitux has been designed to attach to the EGFR, which can be found on



ΠΑΡΑΡΤΗΜΑ Ι ΠΕΡΙΛΗΨΗ ΤΩΝ - eceuropaeu

Erbitux 5mg/ml διάλυμα για έγχυση 2 ΠΟΙΟΤΙΚΗΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ Κάθε ml του διαλύματος για έγχυση περιέχει 5mg cetuximab Κάθε φιαλίδιο των 20ml περιέχει 100mg cetuximab Κάθε φιαλίδιο των 100ml περιέχει 500mg cetuximab



I MELLÉKLET ALKALMAZÁSI ELŐÍRÁS

Erbitux 5 mg/ml oldatos infúzió 2 MINŐSÉGI ÉS MENNYISÉGIÖSSZETÉTEL 5 mg cetuximab 1 ml oldatos infúzióban Egy darab 20 ml-es injekciós üveg 100mg cetuximabot tartalmaz Egy darab 100 ml-es injekciós üveg 500mg cetuximabot tartalmaz A cetuximab emlős sejtvonalban (Sp2/0) rekombináns DNS-technológiával előállított, IgG1



Erbitux 5 mg/ml Infusionslösung - Merck Group

Die Verabreichung von Erbitux kann entweder als Tropfinfusion, mit einer Infusionspumpe oder einem Perfusor erfolgen Da Erbitux nur mit steriler 0,9 iger Kochsalzlösung (9 mg Natriumchlorid/ml) für Injektionszwecke kompatibel ist, darf die Infusionslösung nicht mit anderen intravenös verabreichten Arzneimitteln gemischt werden



ENCePP Plenary meeting 12 November

An agency of the European Union ENCePP Plenary meeting 12 November Introduction to Pharmacogenomics Presented by: Marisa Papaluca Head of Scientific Support Office



THE BIOSIMILAR STORY: THE NEXT CHAPTER OF BIOLOGICS Y

the biosimilar story: the next chapter of biologics y horsmans, md, phd be-1510-bios-076 001

[PDF] Les traitements du cancer du foie - Institut National Du Cancer

[PDF] modern chinese - NetSuite

[PDF] 2017-2018 Chinese Government Scholarship Application

[PDF] Tarifs buffet ? volonté Les apéritifs - Le Pontet | Restaurant Indochine

[PDF] Méthode d 'apprentissage des caractères chinois - Decitre

[PDF] CHU Gabriel-Montpied, place Henri-Dunant ? Clermont-Ferrand

[PDF] annuaire médical - CHU Grenoble Alpes

[PDF] Pour devenir chirurgien

[PDF] ChISTuL RENAL SOLITAR - Arta Medica

[PDF] MP5 - ChloroFil

[PDF] Le bilan azoté - Chambre d 'Agriculture du Tarn

[PDF] Chlorphenamine - Medsafe

[PDF] pH d 'une solution de chlorure d 'ammonium pH = 56

[PDF] Comment expliquer les fluctuations économiques - SES Massena

[PDF] Caryotype humain : Technique Indications